A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics

Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Lin, Joanne, Lee, Stacey L., Russell, Anna M., Huang, Rong Fong, Batt, Micheal A., Chang, Shawn S., Ferrante, Andrea, Verdino, Petra
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2021
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8301669/
https://ncbi.nlm.nih.gov/pubmed/34297759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0254944
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller